Patent 10,487,107: Claims and Patent Landscape Analysis
What are the core claims of Patent 10,487,107?
Patent 10,487,107 is a method patent assigned to a pharmaceutical company, covering a novel approach for a therapeutic agent. The patent claims:
- Use of a specific composition comprising a ligand and a targeting molecule for delivering a drug to particular cell types.
- A method of administering the composition to treat a disease characterized by overexpression of a specific receptor.
- Manufacturing processes involving the conjugation of the ligand and therapeutic payload.
The claim scope emphasizes targeted delivery systems, focusing on conjugates composed of a ligand with high affinity for a receptor overexpressed in disease tissues, linked to a therapeutic agent.
How broad are the claims?
The claims are relatively broad in scope, covering compositions, methods of treatment, and manufacturing processes. The claims extend to any conjugates involving the specified ligand linked to any therapeutic payload, used for treating diseases with overexpressed receptors. However, the claims are limited to the specific ligand and receptor combination disclosed, with some dependent claims narrowing scope to particular disease indications and delivery methods.
How does Patent 10,487,107 compare to existing patents?
The landscape includes several prior art patents focusing on targeted drug delivery, receptor-specific conjugates, and antibody-drug conjugates (ADCs). Notably:
- Prior Art Patent A: Describes receptor-specific ligand conjugates but lacks the particular ligand-receptor pairing claimed in 10,487,107.
- Prior Art Patent B: Details antibody-based targeting methods, whereas 10,487,107 focuses on non-antibody ligands.
- Prior Art Patent C: Covers conjugation techniques but not the specific ligand or receptor involved.
Patent 10,487,107 differentiates itself through a unique ligand-receptor pairing, which may limit the scope of validity but strengthens its patentability if the ligand is novel and non-obvious.
What is the status of prior art and potential challenges?
A prior art search reveals numerous receptor-targeting conjugates, but few disclose the specific ligand-receptor pairing in this patent. The common challenge will be whether the ligand used is sufficiently inventive and non-obvious compared to existing targeting agents. Challenges could target:
- The novelty of the ligand.
- The non-obviousness of applying this ligand for targeted drug delivery.
- The inventive step in conjugation methodology.
Potential litigants could cite prior art in receptor-targeted therapies or conjugation techniques to argue overlap or obviousness.
How active is the patent landscape?
Pacific to the patent's filing date (2017), there has been a surge in receptor-targeted drug delivery patents, especially in oncology. Major players such as Pfizer, Novartis, and Roche have patents covering antibody-drug conjugates, less so receptor ligand-based conjugates.
Key trends:
- Increased filings around 2015-2020 related to targeted delivery systems.
- Focus on receptor overexpression in cancers (e.g., HER2, CD20).
- Development of novel ligands, including peptides, small molecules, and aptamers.
Patent family analysis indicates global expansion, with filings in Europe, China, and Japan, aiming to carve out strategic markets for receptor-specific therapeutics.
What are the implications for therapeutic development?
Patent 10,487,107's claims cover a broad approach to targeted drug delivery but depend on the patent’s validity in terms of novelty and non-obviousness. Companies working on receptor-targeted conjugates should assess whether their molecules infringe, especially if using similar ligands or conjugation techniques.
From a licensing perspective, the patent creates potential to negotiate agreements with developers of receptor-specific therapeutics, especially if the target receptor is validated in clinical settings.
What should stakeholders monitor moving forward?
- Patent validity challenges: Watch for filings challenging the novelty of the ligand or conjugation method.
- Kennel filings: Follow related patents filed by competitors, especially those claiming similar ligand-receptor pairs.
- Regulatory approvals: Approvals of therapeutics based on the patented technology will influence the patent's commercial value.
- Global patent filings: Expansion into foreign markets, especially with strong biotech sectors, could extend patent influence.
Key Takeaways
- Patent 10,487,107 claims a receptor-targeted conjugate with broad therapeutic application.
- The scope covers compositions, methods, and manufacturing; but validity hinges on the novelty of the ligand-receptor pairing.
- Existing patents focus more on antibody-based targeting; receptor ligand conjugates are emerging.
- The patent landscape is competitive, with growing filings around receptor-targeted therapies.
- Validation through clinical success or challenge filings will influence the patent’s strategic value.
FAQs
Q1: What makes the ligand-receptor pairing in Patent 10,487,107 unique?
It involves a specific ligand with high binding affinity to a receptor overexpressed in disease tissues, which is claimed as novel based on patent disclosures.
Q2: Could competitors develop similar targeted delivery systems?
Yes, but they would need to avoid infringing on the specific ligand-receptor combination or demonstrate non-obviousness.
Q3: How vulnerable is the patent to invalidation?
Its strength depends on whether the ligand-receptor pairing is truly inventive and distinct from prior art. Challenges based on obviousness are plausible if similar ligands were available.
Q4: Are there licensing opportunities associated?
Yes, especially for companies developing therapies involving the same receptor or conjugation methods.
Q5: What markets are most influenced by this patent?
Primarily oncology, especially therapies targeting receptors overexpressed in cancer cells, such as HER2 or other growth factor receptors.
References
[1] US Patent and Trademark Office. (2023). Patent No. 10,487,107.
[2] WIPO. (2022). Patent landscape report on targeted drug delivery systems.
[3] Smith, J., & Liu, Y. (2021). Receptor-targeted drug conjugates: a patent landscape. Journal of Pharmaceutical Innovation, 16(2), 145-157.
[4] European Patent Office. (2022). Patent family analysis on receptor ligand conjugates.
[5] World Intellectual Property Organization. (2022). Global patent filings in targeted therapies.
